β-amyloid burden predicts prospective decline in body mass index in clinically normal adults,Neurobiology of Aging

当前位置： X-MOL 学术 › Neurobiol. Aging › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

β-amyloid burden predicts prospective decline in body mass index in clinically normal adults
Neurobiology of Aging ( IF 3.7 ) Pub Date : 2020-09-01 , DOI: 10.1016/j.neurobiolaging.2020.03.002
Jennifer S Rabin ₁ , Zahra Shirzadi ₂ , Walter Swardfager ₃ , Bradley J MacIntosh ₂ , Aaron Schultz ₄ , Hyun-Sik Yang ₅ , Rachel F Buckley ₆ , Jennifer R Gatchel ₇ , Dylan Kirn ₈ , Jeremy J Pruzin ₅ , Trey Hedden ₉ , Nir Lipsman ₁₀ , Dorene M Rentz ₅ , Sandra E Black ₁₁ , Keith A Johnson ₁₂ , Reisa A Sperling ₁₃ , Jasmeer P Chhatwal ₁₃ , ,

Affiliation

Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, Toronto, Ontario, Canada; Harquail Centre for Neuromodulation, Sunnybrook Research Institute, Toronto, Ontario, Canada; Department of Medicine, Division of Neurology, University of Toronto, Toronto, Ontario, Canada; Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, Toronto, Ontario, Canada; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, Toronto, Ontario, Canada; Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ontario, Canada.
Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital; Boston, MA, USA.
Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital; Boston, MA, USA; Florey Institutes of Neuroscience and Mental Health, Melbourne and Melbourne School of Psychological Science, University of Melbourne, Melbourne, Australia.
Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Department of Neurology, Icahn School of Medicine, Mount Sinai, New York, NY, USA.
Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, Toronto, Ontario, Canada; Harquail Centre for Neuromodulation, Sunnybrook Research Institute, Toronto, Ontario, Canada; Department of Medicine, Division of Neurosurgery, University of Toronto, Toronto, Ontario, Canada.
Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, Toronto, Ontario, Canada; Department of Medicine, Division of Neurology, University of Toronto, Toronto, Ontario, Canada.
Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital; Boston, MA, USA; Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital, Boston, MA, USA.
Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital; Boston, MA, USA.

In the present study, we tested the hypothesis that higher amyloid-beta (Aβ) burden at baseline is associated with greater longitudinal decline in body mass index (BMI) in clinically normal adults. Participants from the Harvard Aging Brain Study (n = 312) and the Alzheimer's Disease Neuroimaging Initiative (n = 336) underwent Aβ positron emission tomography at baseline. BMI was assessed longitudinally over a median of >4 years. Linear mixed models showed that higher baseline Aβ burden was significantly associated with greater decline in BMI in both the Harvard Aging Brain Study (t = -1.93; p = 0.05) and Alzheimer's Disease Neuroimaging Initiative cohorts (t = -2.54; p = 0.01), after adjusting for covariates, including cognitive performance and depressive symptoms. In addition, the association of Aβ burden with longitudinal decline in BMI persisted in both cohorts after excluding participants with diabetes/endocrine disturbances and participants classified as underweight or obese (BMI <18.5 or >30). These findings suggest that decline in BMI in clinically normal adults may be an early manifestation related to cerebral amyloidosis that precedes objective cognitive impairment. Therefore, unintentional BMI decline in otherwise healthy individuals might alert clinicians to increased risk of Alzheimer's disease.

中文翻译：

β-淀粉样蛋白负荷可预测临床正常成人体重指数的预期下降

在本研究中，我们检验了这样一个假设，即基线时较高的淀粉样蛋白 (Aβ) 负荷与临床正常成人体重指数 (BMI) 的更大纵向下降相关。来自哈佛大脑老化研究 (n = 312) 和阿尔茨海默病神经影像学计划 (n = 336) 的参与者在基线时接受了 Aβ 正电子发射断层扫描。BMI 被纵向评估超过 4 年的中位数。线性混合模型显示，在哈佛大脑老化研究 (t = -1.93; p = 0.05) 和阿尔茨海默病神经影像学倡议队列 (t = -2.54; p = 0.01) 中，较高的基线 Aβ 负荷与 BMI 的较大下降显着相关，在调整协变量后，包括认知表现和抑郁症状。此外，在排除糖尿病/内分泌紊乱的参与者和归类为体重不足或肥胖（BMI <18.5 或 >30）的参与者后，Aβ 负担与 BMI 纵向下降的关联在两个队列中仍然存在。这些发现表明，临床正常成人 BMI 的下降可能是与大脑淀粉样变性相关的早期表现，该表现先于客观认知障碍。因此，健康个体的 BMI 无意下降可能会提醒临床医生注意阿尔茨海默病的风险增加。这些发现表明，临床正常成人 BMI 的下降可能是与大脑淀粉样变性相关的早期表现，该表现先于客观认知障碍。因此，健康个体的 BMI 无意下降可能会提醒临床医生注意阿尔茨海默病的风险增加。这些发现表明，临床正常成人 BMI 的下降可能是与大脑淀粉样变性相关的早期表现，该表现先于客观认知障碍。因此，健康个体的 BMI 无意下降可能会提醒临床医生注意阿尔茨海默病的风险增加。

更新日期：2020-09-01

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11